Creatine for treating muscle disorders

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Kley, Rudolf A ^a   Vorgerd, M ^b   Tarnopolsky, M A ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b NONE

Author keywords

*Dietary supplements; Creatine *therapeutic use ; Muscle contraction drug effects ; Muscle strength *drug effects; physiology ; Muscular diseases *drug therapy ; Muscular dystrophies drug therapy

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE; GLUTAMINE; PLACEBO;

AEROBIC EXERCISE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; GLYCOGEN STORAGE DISEASE TYPE 6; HUMAN; LEAN BODY WEIGHT; META ANALYSIS; MUSCLE CONTRACTION; MUSCLE DISEASE; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE STRENGTH; MUSCULAR DYSTROPHY; MYALGIA; REVIEW; SYSTEMATIC REVIEW;

EID: 35348976834     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004760.pub2     Document Type: Review

References (76)

1. Escolar 2005 {published data only} Escolar DM, Buyse G, Henricson E, Leshner R, Florence J, Mayhew J, et al.CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Annals of Neurology 2005;58(1):151-5. [MEDLINE: 15984021].
2. Klopstock 2000 {published and unpublished data} Klopstock T, Querner V, Schmidt F, Gekeler F, Walter M, Hartard M, et al.A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 2000;55(11):1748-51. [MEDLINE: 11113239].
3. Kornblum 2005 {published and unpublished data} Kornblum C, Schröder R, Müller K, Vorgerd M, Eggers J, Bogdanow M, et al.Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo-controlled, double-blind 31P-MRS crossover study. European Journal of Neurology 2005;12(4):300-9. [MEDLINE: 15804248].
4. Louis 2003 {published and unpublished data} Louis M, Lebacq J, Poortmanns JR, Belpaire-Dethiou MC, Devogelaer JP, et al.Beneficial effects of creatine supplementation in dystrophic patients. Muscle & Nerve 2003;27(5):604-10. [MEDLINE: 12707981].
5. Schneider-Gold 2003 {published data only} Schneider-Gold C, Beck M, Wessig C, George A, Kele H, Reiners K, et al.Creatine monohydrate in DM2/PROMM: a double-blind placebo-controlled clinical study. Neurology 2003;60(3):500-2. [MEDLINE: 12578937].
6. Tarnopolsky 1997 {published and unpublished data} Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle & Nerve 1997;20(12):1502-9. [MEDLINE: 9390662].
7. Tarnopolsky 2004a {published and unpublished data} Tarnopolsky MA, Mahoney DJ, Vajsar J, Rodriguez C, Doherty TJ, Roy BD, et al.Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 2004;62(10):1771-7. [MEDLINE: 15159476].
8. Tarnopolsky 2004b {published and unpublished data} Tarnopolsky M, Mahoney D, Thompson T, Naylor H, Doherty TJ. Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1. Muscle & Nerve 2004;29(1):51-8. [MEDLINE: 14694498].
9. Vorgerd 2000 {published and unpublished data} Vorgerd M, Grehl T, Jager M, Muller K, Freitag G, Patzold T, et al.Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial. Archives of Neurology 2000;57(7):956-63. [MEDLINE: 10891977].
10. Vorgerd 2002 {published and unpublished data} Vorgerd M, Zange J, Kley R, Grehl T, Husing A, Jager M, et al.Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study. Archives of Neurology 2002;59(1):97-101. [MEDLINE: 11790236].
11. Walter 2000 {published and unpublished data} Walter MC, Lochmuller H, Reilich P, Klopstock T, Huber R, Hartard M, et al.Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study. Neurology 2000;54(9):1848-50. [MEDLINE: 10802796].
12. Walter 2002 {published and unpublished data} Walter MC, Reilich P, Lochmuller H, Kohnen R, Schlotter B, Hautmann H, et al.Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study. Journal of Neurology 2002;249(12):1717-22. [MEDLINE: 12529796].
13. Barisic 2002 Barisic N, Bernert G, Ipsiroglu O, Stromberger C, Muller T, Gruber S, et al.Effects of oral creatine supplementation in a patient with MELAS phenotype and associated nephropathy. Neuropediatrics 2002;33(3):157-61.
14. Beurey 1967 Beurey J, Duc M, Weber M, Gurecki H, Perello R. Trial therapy of acute polymyositis with phosphocreatine [Essai de traitement de polymyosite aigue par phosphocreatine]. Bulletin de la Société Française de Dermatologie et Syphiligraphie 1967;74(2):276-80.
15. Borchert 1999 Borchert A, Wilichowski E, Hanefeld F. Supplementation with creatine monohydrate in children with mitochondrial encephalomyopathies. Muscle & Nerve 1999;22(9):1299-300. [MEDLINE: 10454733].
16. Duperrat 1972 Duperrat B, Puissant A, Mallard D, Jourdain JC, Thomas D. Dermatomyositis with cardiac involvement and trial treatment with phosphocreatine [Dermatomyosite avec atteinte cardiaque et essai de traitement par la phosphocréatine]. Bulletin de la Société Française de Dermatologie et Syphiligraphie 1972;79(3):208-10.
17. Felber 2000 Felber S, Skladal D, Wyss M, Kremser C, Koller A, Sperl W. Oral creatine supplementation in Duchenne muscular dystrophy: a clinical and 31P magnetic resonance spectroscopy study. Neurological Research 2000;22(2):145-50.
18. Freddi 1979 Freddi A, Paci A, DeCiantis R, Lancia G, DeSantis L. Phosphocreatinine in myotonic dystrophy (Steinert's disease). Lancet 1979;30(1 (8131)):1400-1.
19. Hagenfeldt 1994 Hagenfeldt L, von Dobeln U, Solders G, Kaijser L. Creatine treatment in MELAS. Muscle & Nerve 1994;17(10):1236- 7.
20. Komura 2003 Komura K, Hobbiebrunken E, Wilichowski EK, Hanefeld FA. Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. Pediatric Neurology 2003;28(1):53-8.
21. Matsumura 2004 Matusmura T, Yokoe M, Nakamori M, Hattori N, Saito T, Nozaki S, et al.A clinical trial of creatine monohydrate in muscular dystrophy patients. Rinsho Shinkeigaku 2004;44(10):661-6. [MEDLINE: 15568480].
22. Sejersen 2000 Sejersen T, Hovmoller M, Hok L, Nordmark-Andersson E, Winberg P, Nylander E, et al.Lack of detectable effect of creatine supplementation on skeletal muscle or cardiac function in Duchenne muscular dystrophy. Neuromuscular Disorders 2000;10:375.
23. Stout 2001 Stout JR, Eckerson JM, May E, Coulter C, Bradley-Popovich GE. Effects of resistance exercise and creatine supplementation on myasthenia gravis: a case study. Medicine and Science in Sports and Exercise 2001;33(6):869-72.
24. Tarnopolsky 1999 Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999;52(4):854-7.
25. Andreassen 2001 Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, et al.Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiology of Disease 2001;8(3):479-91.
26. Brose 2003 Brose A, Parise G, Tarnopolsky MA. Creatine supplementation enhances isometric strength and body composition improvements following strength exercise training in older adults. The journals of gerontology. Series A, Biological sciences and medical sciences 2003;58(1):11-9.
27. Burke 2003 Burke DG, Chilibeck PD, Parise G, Candow DG, Mahoney D, Tarnopolsky M. Effect of creatine and weight training on muscle creatine and performance in vegetarians. Medicine and Science in Sports and Exercise 2003;35(11):1946-55.
28. Casey 1996 Casey A, Constantin-Teodosiu D, Howell S, Hultman E, Greenhaff PL. Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. The American Journal of Physiology 1996;271(1 Pt 1):E31-7.
29. Chetlin 2004 Chetlin RD, Gutmann L, Tarnopolsky MA, Ullrich IH, Yeater RA. Resistance training exercise and creatine in patients with Charcot-Marie-Tooth disease. Muscle & Nerve 2004;30(1):69-76.
30. Chilibeck 2004 Chilibeck PD, Stride D, Farthing JP, Burke DG. Effect of creatine ingestion after exercise on muscle thickness in males and females. Medicine and Science in Sports and Exercise 2004;36:1781- 8.
31. Chilibeck 2005 Chilibeck PD, Chrusch MJ, Chad KE, Shawn Davison K, Burke DG. Creatine monohydrate and resistance training increase bone mineral content and density in older men. The journal of Nutrition, Health & Aging 2005;9:352-3.
32. Chrusch 2001 Chrusch MJ, Chilibeck PD, Chad KE, Davison KS, Burke DG. Creatine supplementation combined with resistance training in older men. Medicine and Science in Sports and Exercise 2001;33(12):2111-7.
33. Dechent 1999 Dechent P, Pouwels PJ, Wilken B, Hanefeld F, Frahm J. Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. American Journal of Physiology 1999;277(3 Pt 2):R698-704.
34. Dedeoglu 2003 Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, et al.Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of Neurochemistry 2003;85(6):1359-67.
35. Ferrante 2000 Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, et al.Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. Journal of Neuroscience 2000; 20(12):4389-97.
36. Greenwood 2003 Greenwood M, Kreider RB, Melton C, Rasmussen C, Lancaster S, Cantler E, et al.Creatine supplementation during college football training does not increase the incidence of cramping or injury. Molecular and Cellular Biochemistry 2003;244(1-2):83-8.
37. Groeneveld 2003 Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, et al.A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Annals of Neurology 2003;53(4):437-45.
38. Guimbal 1993 Guimbal C, Kilimann MW. Na(+)-dependent creatine transporter in rabbit brain, muscle, heart, and kidney. cDNA cloning and functional expression. The Journal of Biological Chemistry 1993;268(12):8418-21.
39. Guthmiller 1994 Guthmiller P, van Pilsum JF, Boen JR, McGuire DM. Cloning and sequencing of rat kidney L-arginine: glycine amidinotransferase. Studies on the mechanism of regulation by growth hormone and creatine. The Journal of Biological Chemistry 1994;269(26):17556-60.
40. Harris 1992 Harris RC, Soderlund K, Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clinical Science 1992;83(3):367-74.
41. Hersch 2006 Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, et al.Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG. Neurology 2006;66(2): 250-2.
42. Hultman 1996 Hultman E, Soderlund K, Timmons JA, Cederlad G, Greenhaff PL. Muscle creatine loading in men. Journal of Applied Physiology 1996; 81(1):232-7.
43. Klivenyi 1999 Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, et al.Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine 1999;5(3):347-50.
44. Klivenyi 2004 Klivenyi P, Calingasan NY, Starkov A, Stavrovskaya IG, Kristal BS, Yang L, et al.Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiology of Disease 2004;15(3):610-7.
45. Kreider 2003 Kreider RB, Melton C, Rasmussen CJ, Greenwood M, Lancaster S, Cantler EC, et al.Long-term creatine supplementation does not significantly affect clinical markers of health in athletes. Molecular and Cellular Biochemistry 2003;244(1-2):95-104.
46. Malcon 2000 Malcon C, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine administration against NMDA and malonate toxicity. Brain Research 2000;860(1-2):195-8.
47. Manzur 2004 Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews 2004, Issue 2.Art. No.: CD003725. DOI: 10.1002/14651858.CD003725.pub3.
48. Matthews 1990 Matthews PM, Arnold DL. Phosphorus magnetic resonance spectroscopy of brain in mitochondrial cytopathies. Annals of Neurology 1990;28(6):839-40.
49. Matthews 1991 Matthews PM, Allaire C, Shoubridge EA, Karpati G, Carpenter S, Arnold DL. In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondrial disease. Neurology 1991;41 (1):114-20.
50. Matthews 1998 Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, et al.Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. Journal of Neuroscience 1998;18(1):156-63.
51. Mazzini 2001 Mazzini L, Balzarini C, Colombo R, Mora G, Pastore I, DeAmbrogio R, et al.Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. Journal of the Neurological Sciences 2001;191(1-2):139-44.
52. Mihic 2000 Mihic S, MacDonald JR, McKenzie S, Tarnopolsky MA. Acute creatine loading increases fat-free mass, but does not affect blood pressure, plasma creatinine, or CK activity in men and women. Medicine and Science in Sports and Exercise 2000;32(2):291-6.
53. Parise 2001 Parise G, Mihic S, MacLennan D, Yarasheski KE, Tarnopolsky MA. Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis. Journal of Applied Physiology 2001;91(3):1041-7.
54. Park 1994 Park JH, Vital TL, Ryder NM, Hernanz-Schulman M, Partain CL, Price RR, et al.Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis and Rheumatism 1994;37(5):736-46.
55. Park 1995 Park JH, Olsen NJ, King L, Jr, Vital T, Buse R, Kari S, et al.Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis. Arthritis and Rheumatism 1995;38(1):68-77.
56. Passaquin 2002 Passaquin AC, Renard M, Kay L, Challet C, Mokhtarian A, Wallimann T, et al.Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscular Disorders 2002;12(2):172-82.
57. Persky 2003 Persky AM, Muller M, Derendorf H, Grant M, Brazeau GA, Hochhaus G. Single- and multiple-dose pharmacokinetics of oral creatine. Journal of Clinical Pharmacology 2003;43(1):29-37.
58. Poortmans 1999 Poortmans JR, Francaux M. Long-term oral creatine supplementation does not impair renal function in healthy athletes. Medicine and Science in Sports and Exercise 1999;31(8):1108-10.
59. Poortmans 2000 Poortmans JR, Francaux M. Adverse effects of creatine supplementation: fact or fiction?. Sports Medicine (Auckland, New Zealand) 2000; 30(3):155-70.
60. Poortmans 2005 Poortmans JR, Kumps A, Duez P, Fofonka A, Carpentier A, Francaux M. Effect of oral creatine supplementation on urinary methylamine, formaldehyde, and formate. Medicine and Science in Sports and Exercise 2005;37(10):1717-20.
61. Pulido 1998 Pulido SM, Passaquin AC, Leijendekker WJ, Challet C, Wallimann T, Ruegg UT. Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells. FEBS Letters 1998;439(3):357-62.
62. Rawson 2004 Rawson ES, Persky AM, Price TB, Clarkson PM. Effects of repeated creatine supplementation on muscle, plasma, and urine creatine levels. Journal of Strength and Conditioning Research 2004;18(1):162-7.
63. Rose 2004 Rose MR, Tawil R. Drug treatment for facioscapulohumeral muscular dystrophy. Cochrane Database of Systematic Reviews 2004, Issue 2.Art. No.: CD002276. DOI:10.1002/14651858.CD002276.pub2.
64. Roy 2002 Roy BD, Bourgeois JM, Mahoney DJ, Tarnopolsky MA. Dietary supplementation with creatine monohydrate prevents corticosteroid-induced attenuation of growth in young rats. Canadian Journal of Physiology and Pharmacology 2002;80(10):1008-14.
65. Shao 2006 Shao A, Hathcock JN. Risk assessment for creatine monohydrate. Regulatory Toxicology and Pharmacology 2006;45(3): 242-51.
66. Shefner 2004 Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, et al.A clinical trial of creatine in ALS. Neurology 2004;63(10):1656-61.
67. Sullivan 2000 Sullivan PG, Geiger JD, Mattson MP, Scheff SW. Dietary supplement creatine protects against traumatic brain injury. Annals of Neurology 2000;48(5):723-9.
68. Tarnopolsky 1999a Tarnopolsky MA, Parise G. Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease. Muscle & Nerve 1999;22(9):1228-33.
69. Tarnopolsky 1999b Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999;52(4):854-7.
70. Tarnopolsky 2000 Tarnopolsky MA, MacLennan DP. Creatine monohydrate supplementation enhances high-intensity exercise performance in males and females. International Journal of Sport Nutrition and Exercise Metabolism 2000;10(4):452-63.
71. Tarnopolsky 2001 Tarnopolsky MA, Parshad A, Walzei B, Schlattner U, Wallimann T. Creatine transporter and mitochondrial creatine kinase protein content in myopathies. Muscle & Nerve 2001;24(5):682-8.
72. Terjung 2000 Terjung RL, Clarkson P, Eichner ER, Greenhaff PL, Hespel PJ, Israel RG, et al.American College of Sports Medicine round table. The physiological and health effects of oral creatine supplementation. Medicine and Science in Sports and Exercise 2000;32(3):706-17.
73. Verbessem 2003 Verbessem P, Lemiere J, Eijnde BO, Swinnen S, Vanhees L, Van Leemputte M, et al.Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 2003;61(7): 925-30.
74. Wyss 1992 Wyss M, Smeitink J, Wevers RA, Wallimann T. Mitochondrial creatine kinase: a key enzyme of aerobic energy metabolism. Biochimica et biophysica acta 1992;1102(2):119-66.
75. Wyss 1998 Wyss M, Felber S, Skladal D, Koller A, Kremser C, Sperl W. The therapeutic potential of oral creatine supplementation in muscle disease. Medical Hypotheses 1998;51(4):333-6. [MEDLINE: 9824841].
76. Zhu 2004 Zhu S, Li M, Figueroa BE, Liu A, Stavrovskaya IG, Pasinelli P, et al.Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. The Journal of Neuroscience 2004;24(26): 5909-12.